professor of surgical oncology
Radboud University Medical Center, Nijmegen, the Netherlands
Dr. Hans de Wilt is Professor of Surgical Oncology at Radboud University Medical Center, the Netherlands. Dr. De Wilt is an active member of the Dutch Society of ColoRectal Surgeons and president of the Dutch Colorectal Cancer Group. He initiated several international multicenter studies on organ preservation preservation and treatment of (advanced) colorectal cancer. He published more than 500 papers in peer reviewed journals and supervised 30 PhD students. He recently completed a study examining outcomes following the use of Labetuzumab (In-DOTA-labetuzumab-IRDye800CW), a humanized monoclonal antibody which specifically targets CEA in patients with peritoneal carcinomatosis of a colorectal origin. His initial feasibility study demonstrated that this method of evaluation was well tolerated and resulted in the intraoperative detection of cancer not diagnosed on routine imaging. He is currently planning a prospective trial with similar dual labbeld antibodies in rectal cancer.
Disclosure information not submitted.
Precision Surgery with Tumor Marker Directed Labeling of Cancer Cells
Sunday, May 11, 2025
4:27 PM – 4:40 PM PT
